New implant could help fight opioid addiction

NCT ID NCT06216132

Completed Disease control Sponsor: Akyso Therapeutics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a new implant that slowly releases naltrexone, a medication used to treat opioid use disorder. The implant is placed under the skin and left for three months. The trial involved 16 healthy adults to check safety and how the drug enters the bloodstream. It is a first step toward a potential treatment that could help people stay on medication without daily pills or injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: naltrexone implant (extended-release naltrexone in a biodegradable implant)
What this could lead to: If successful, this implant could provide a long-lasting, steady-dose treatment option for opioid use disorder, potentially improving adherence and reducing relapse risk.
What could go wrong: This is a very early Phase 1 safety study in only 16 healthy adults, not people with opioid use disorder. It does not test effectiveness, and the implant requires insertion and removal procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

JBR Clinical Research

Salt Lake City, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.